A Study of DS9051b
Phase 1
40
about 2.3 years
18+
3 sites in FL, NY, RI
What this study is about
This trial is testing a treatment called DS9051b in people with advanced or metastatic adrenocortical carcinoma and metastatic castration-resistant prostate cancer. The goal is to see if the treatment is safe, well-tolerated, and shows some early signs of effectiveness.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take DS9051b
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants Reporting Dose-limiting Toxicities (DLTs), Treatment-emergent Adverse Events (TEAEs), TEAEs Associated With Treatment Discontinuation, Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESI) - All Patients
Secondary: Duration of Response by Investigator Assessment in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer, Objective Response by Investigator Assessment in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer, Progression-free Survival by Investigator Assessment in Participants With Advanced or Metastatic Adrenocortical Carcinoma
Oncology